Teva to obtain exclusive worldwide rights to develop and commercialize BD9 multibody for potential treatment for Atopic Dermatitis and Asthma.
Sidley represented Biolojic Design Ltd. ("Biolojic"), a biotechnology company that uses computational biology and artificial intelligence to transform antibodies into intelligent medicinal solutions, in an exclusive license agreement with Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) to develop a potential novel antibody-based therapy for the treatment of Atopic Dermatitis and Asthma.
Under the terms of the agreement, Teva will receive exclusive rights to develop, manufacture, and commercialize BD9 worldwide. In exchange, Biolojic will receive an upfront payment, and will be eligible to receive subsequent milestone payments over the next several years, based on the achievement of certain pre-clinical, clinical, regulatory, and commercial milestones. Biolojic is also eligible to receive tiered royalties in the mid-single to low-double digit on product sales should Teva successfully commercialize a therapy.
BD9 is a dual specific antibody that can block both TSLP (Thymic stromal lymphopoietin) and IL-13, and has the potential to deliver treatment across typically TH2-driven inflammatory diseases, such as atopic dermatitis and asthma. Existing drugs currently approved by health authorities focus on only one of these two drivers of inflammation, and do not respond to pathway dynamics. When TSLP or IL13 is upregulated, BD9 can bind to either target with both arms and with high affinity, therefore having the potential to help more patients and improve outcomes.
The team was led Asher Rubin (Technology and Life Sciences Transactions), and Eden Moalem (Emerging Companies and Venture Capital), and included Yahel Kaplan (Emerging Companies and Venture Capital), and Cassidy A. Pomeroy-Carter (Technology and Life Sciences Transactions).
For additional information, please refer to the press release.